logo
logo

Zambon Launches Xadago® (Safinamide) in the U.K. for Patients with Mid- to Late-Stage Parkinson’s Disease

avatar
Henry Booker

Results from 6 month double-blind controlled studies suggest that safinamide shows statistically significant effects on motor fluctuations ON/OFF time without increasing the risk of developing troublesome dyskinesia.

Zambon has the rights to develop and commercialize Xadago globally, excluding Japan and other key territories where Meiji Seika has the rights to develop and commercialize the compound.

Borgohain, Rupam; Szasz, Jozsef; Stanzione, Paolo; Meshram, Chandrashekhar; Bhatt, Mohit H et al.

Early-stage patients are more easily managed on L-dopa.

Zambon S.p.A. produces high quality products thanks to the management of the whole production chain which involves Zach Zambon chemical , a privileged partner for API, custom synthesis and generic products.

Important Notices This document contains forward-looking statements, including without limitation about 1 Newron s ability to develop and expand its business, successfully complete development of its current product candidates and current and future collaborations for the development and commercialisation of its product candidates and reduce costs including staff costs , 2 the market for drugs to treat CNS diseases and pain conditions, 3 Newron s anticipated future revenues, capital expenditures and financial resources, and 4 assumptions underlying any such statements.

collect
0
avatar
Henry Booker
guide
Zupyak is a free content platform for publishing and discovering stories, software and startups.